FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.

Melanoma Diagnoses Can Vary Widely Among Pathologists

Melanoma Diagnoses Can Vary Widely Among Pathologists

When researchers sent sample slides to pathologists for review, the assessments varied widely and some pathologists even disagreed with their own initial assessment when retested months later.

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.

Cancer Recurrence Fear Reduced by Novel Psychological Intervention

Cancer Recurrence Fear Reduced by Novel Psychological Intervention

'Conquer Fear' decreased fear among survivors of breast and colorectal cancer and melanoma compared with relaxation techniques.

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.

Noninvasive 2-Gene Test Helps Distinguish Melanoma From Nonmelanoma

Noninvasive 2-Gene Test Helps Distinguish Melanoma From Nonmelanoma

Two-gene pigmented lesion test classifies skin lesions as melanoma or nonmelanoma, helping with diagnostic challenges faced with the visual image and pattern recognition approach.

Assessment of Melanoma Screening Practices Produces Data-Driven, Risk-Based Guidelines

Assessment of Melanoma Screening Practices Produces Data-Driven, Risk-Based Guidelines

Dermatologist assessment of screening practices addresses the lack of a national consensus on screening guidelines for melanoma.

Psoriasis May Increase Risk of Melanoma and Hematologic Cancers

Psoriasis May Increase Risk of Melanoma and Hematologic Cancers

Patients with psoriasis had 1.53 times greater risk of developing a malignancy, regardless of the type of psoriasis therapy they are receiving.

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.

Kinase Inhibitors: Managing Adverse Effects in the Treatment of Metastatic Melanoma

Kinase Inhibitors: Managing Adverse Effects in the Treatment of Metastatic Melanoma

Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.

Antidiabetes Drug Holds Promise as Adjuvant Therapy for Older Patients with Melanoma

Antidiabetes Drug Holds Promise as Adjuvant Therapy for Older Patients with Melanoma

Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

Researchers sought to conduct a cost-effectiveness analysis of immunotherapy for patients with advanced melanoma.

Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer

Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer

Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.

Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline

Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline

Using statistical models, predictions were made for death rates from melanoma in 3 three countries and based on availability of a treatment.

Computer 'Deep Learning' Algorithm Matches Dermatologists at Classifying Melanomas

Computer 'Deep Learning' Algorithm Matches Dermatologists at Classifying Melanomas

Researchers compared the ability of an artificial-intelligence algorithm to recognize and classify skin cancers with the clinical evaluations of dermatologists.

IFN Induction No Better Than Observation for Intermediate-risk Melanoma

IFN Induction No Better Than Observation for Intermediate-risk Melanoma

Induction therapy with intravenous interferon α-2b appeared to be no better than observation alone for the management of patients with intermediate-risk melanoma.

Customers Find Useful Information in Results from Direct-to-Consumer Genetic Testing

Customers Find Useful Information in Results from Direct-to-Consumer Genetic Testing

Results of a series of Internet surveys revealed customers' perceptions of harms, benefits, and limitations of genetic information received from direct-to-consumer genetic testing.

Beach Umbrella Not Enough for Protection from UV Rays

Beach Umbrella Not Enough for Protection from UV Rays

Comparison studied the effectiveness of sun protection offered by a beach umbrella alone with that of sunscreen with a high sun protection factor.

Melanoma Incidence Still on the Rise in Parts of the United States

Melanoma Incidence Still on the Rise in Parts of the United States

Melanoma incidence varies by region, and many states have experienced an increase.

Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma

Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma

A review of data from three large, prospective studies examined a potential association between alcoholic beverage consumption and risk of melanoma.

Study Identifies Factors Associated With Outcomes After Dabrafenib + Trametinib

Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors. In this study, therefore, researchers sought to examine the incidence of neurotoxicity across anti-CTLA-4 and anti-PD-1 antibodies at a single institution.

More Than Half of Melanomas Are Self-Detected, Especially by Women

More Than Half of Melanomas Are Self-Detected, Especially by Women

More melanomas are self-detected by women; men tend to have more melanomas in less visible locations.

Psychoeducational Intervention Effective for Reducing Fear of Melanoma Recurrence

Psychoeducational Intervention Effective for Reducing Fear of Melanoma Recurrence

A newly developed, evidence-based psychoeducational intervention effectively reduced fear of cancer recurrence and stress in patients at high risk for developing another melanoma.

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

Treatment with pembrolizumab better maintained health-related quality of life compared with chemotherapy in patients with advanced melanoma refractory to ipilimumab.

Experimental Drug Shows Promise in Melanoma Treatment

Experimental Drug Shows Promise in Melanoma Treatment

Pevonedistat was effective for inhibiting proliferation of melanoma cell lines in vitro, research indicates.

Supportive Care Needs Assessed in Localized Cutaneous Melanoma

Supportive Care Needs Assessed in Localized Cutaneous Melanoma

Patients with localized melanoma see their supportive care needs peak at their initial cancer diagnosis and if they experience disease recurrence.

Study Supports Use of PD-1 Inhibitors in Acral, Mucosal Melanomas

Response rates with PD-1 inhibitors in patients with acral and mucosal melanomas were similar to previously reported rates in patients with cutaneous melanoma.

Some Gene Variants Increase the Risk for Melanoma in People With Red Hair, Freckling

Some Gene Variants Increase the Risk for Melanoma in People With Red Hair, Freckling

Variants of the MC1R gene, associated with red hair, pale skin, and freckles, increases the number of genetic mutations related to skin cancer and the level of other gene mutations, further increasing the risk for skin cancer.

Data Confirm Benefit of Cobimetinib and Vemurafenib in Melanoma

Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.

USPSTF: Evidence Lacking to Recommend Full-body Skin Cancer Screens

USPSTF: Evidence Lacking to Recommend Full-body Skin Cancer Screens

New report doesn't change Task Force's prior statement on skin cancer screening issued in 2009

Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries

Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries

Training primary care providers (PCP) to detect early melanoma led to increased melanoma diagnoses, but had little impact on skin surgeries or dermatology visits.

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care

[Cancer Informatics] In this research, a microsimulation model framework is used to examine the impact of simultaneously altering curative treatment approaches in different phases of melanoma treatment.

Study Better Characterizes Immunotherapy-related Skin Toxicities

Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.

De Novo Melanomas May Be More Aggressive Than Nevus-associated Lesions

De novo melanomas, which arise from clinically normal skin with no associated nevus, may be more aggressive than nevus-associated melanomas.

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

In addition to improving overall survival compared with dacarbazine in patients with advanced melanoma, nivolumab maintains baseline levels of health-related quality of life to ultimately confer long-term quality of survival benefit.

Primary Care Melanoma Screening Does Not Cause Major Adverse Consequences

Primary Care Melanoma Screening Does Not Cause Major Adverse Consequences

Population-based screening for melanoma performed by primary care providers does not cause substantial harm with respect to skin surgeries and dermatology visits.

Outcomes Are Not Improved With Pegylated Interferon Alpha-2a vs Interferon Alpha-2a

Outcomes Are Not Improved With Pegylated Interferon Alpha-2a vs Interferon Alpha-2a

PEG-IFN did not improve improve outcomes for patients with melanoma compared with IFN. Furthermore, patients receiving PEG-IFN were more likely to discontinue treatment due to toxicity.

Disease-Free Status Is Achieved by Combining Immunotherapy Treatments in Patient With Metastatic Melanoma

A patient with refractory metastatic melanoma was successfully treated with a novel combination of 2 different types of immunotherapy.

Soles of the Feet Should Also Be Checked for Skin Cancer

Soles of the Feet Should Also Be Checked for Skin Cancer

Cutaneous melanoma is rare on feet, but often advanced at point of diagnosis.

Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

Pembrolizumab provides benefit over ipilimumab in patients with advanced melanoma, regardless of tumor PD-L1 expression status or number of prior therapies, a study presented at the 2016 ASCO Annual Meeting has shown.

Modified Thiazole Benzenesulfonamide Demonstrates Anticancer Activity in Melanoma

A newly discovered synthesized drug reduced the viability of melanoma cells without affecting normal cells in cell culture and mouse xenograft models of the disease. The drug, HA15, is a type of thiazole benzenesulfonamide.

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.

Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma

Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma

At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.

Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.

Combination of Radiation and Immunotherapy Shows Promise in Melanoma

Combination of Radiation and Immunotherapy Shows Promise in Melanoma

Combining radiation treatments with a new generation of immunotherapies is showing promise in the treatment of melanoma, according to a recent review.

Liquid Biopsy Found Comparable to Standard Tissue Biopsy in Identifying BRAF V600 Mutation Status

Plasma from a blood draw can be used to test for BRAF V600 mutations in advanced cancers in just 90 minutes, and results were comparable to using tissue biopsy.

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.

A Protein Could Predict the Response to Immunotherapy in Metastatic Melanoma

A Protein Could Predict the Response to Immunotherapy in Metastatic Melanoma

The Bim protein might predict which patients could be successfully treated with immunotherapy for metastatic melanoma.

ATS: Aggressive Melanoma Linked to Untreated Sleep Apnea

ATS: Aggressive Melanoma Linked to Untreated Sleep Apnea

New study highlights the importance of diagnosing and treating obstructive sleep apnea because of possible cancer connection.

Developments in Intralesional Therapy for Metastatic Melanoma

Developments in Intralesional Therapy for Metastatic Melanoma

[Cancer Control] This research explores the efficacy of intralesional therapy as a treatment option for patients with unresectable, locally advanced, or metastatic melanoma.

Pembrolizumab Achieves Response and Increased Survival in Melanoma

Pembrolizumab Achieves Response and Increased Survival in Melanoma

Overall objective responses occurred in one-third of patients with melanoma who were treated with pembrolizumab in a phase 1b clinical trial.

SPF30 Sunscreens Delay Melanoma in Preclinical Model

SPF30 Sunscreens Delay Melanoma in Preclinical Model

Melanoma onset was delayed by applying sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B light in a mouse model of the disease.

Study Pools Data to Evaluate Melanoma Outcomes After Pembrolizumab

Study Pools Data to Evaluate Melanoma Outcomes After Pembrolizumab

Among patients with advanced melanoma, the human PD-1-blocking antibody pembrolizumab was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months.

Melanoma Tumor Cells Respond Differently to Therapy in Elderly Patients Than in Younger Patients

Melanoma Tumor Cells Respond Differently to Therapy in Elderly Patients Than in Younger Patients

Therapy for the elderly with melanoma may be affected by findings that aged tumor cells in melanoma behave differently than younger tumor cells.

Sun Exposure Beneficial Despite the Risk of Melanoma

Sun Exposure Beneficial Despite the Risk of Melanoma

Though sunbathers are at an increased risk of developing skin cancer, women who sunbathe are likely to live longer than those who avoid the sun.

Microneedle Patch Delivers Localized Immunotherapy for Melanoma

Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.

MC1R Variants May Increase Melanoma Risk, Even Without Sun Exposure

MC1R Variants May Increase Melanoma Risk, Even Without Sun Exposure

Variant of gene linked to skin pigmentation may be tied to higher melanoma risk.

Higher Mole Count Doesn't Always Correspond to Higher Melanoma Risk

Higher Mole Count Doesn't Always Correspond to Higher Melanoma Risk

Physicians shouldn't rely on mole count as the only reason to perform skin exams for melanoma.

HIV Drug Could Re-sensitize Therapy-resistant Melanoma

HIV Drug Could Re-sensitize Therapy-resistant Melanoma

The expression of the PAX3 and MITF genes in melanoma can cause early, nonmutational, reversible drug resistance; tissues that express these genes can then later develop mutational, irreversible drug resistance. The HIV drug nelfinavir can prevent this resistance.

Prognosis Poor for Women With Pregnancy-Associated Melanoma

Prognosis Poor for Women With Pregnancy-Associated Melanoma

Among women aged up to 49 years with a pregnancy-associated melanoma, recurrence rates were higher than seen in other groups.

Melanoma Therapy Associated With Cutaneous Events

Melanoma Therapy Associated With Cutaneous Events

Anti-programmed cell death-1 therapy tied to lichenoid reactions, eczema, vitiligo

Biomarker for Class 1 Uveal Melanoma Correlates with Metastatic Disease

Biomarker for Class 1 Uveal Melanoma Correlates with Metastatic Disease

A new biomarker measurement might improve the accuracy of prognostic testing and precision medicine in uveal melanoma.

Conventional Criteria May Underestimate Response to Treatment in Advanced Melanoma

Conventional Criteria May Underestimate Response to Treatment in Advanced Melanoma

RECIST v1.1 may underestimate the treatment response in patients with advanced melanoma treated with pembrolizumab.

Fewer Total Nevi, More Atypical Nevi Linked With Thick Melanomas in Younger Patients

Fewer Total Nevi, More Atypical Nevi Linked With Thick Melanomas in Younger Patients

Among younger patients, thick melanomas may be commonly found in those with fewer total nevi but more atypical nevi.

PRAME in Class 1 Uveal Melanoma Predicts Metastasis

PRAME in Class 1 Uveal Melanoma Predicts Metastasis

PRAME mRNA expression is independent prognostic biomarker in Class 1 uveal melanoma.

Melanoma Visualized in Live Zebrafish From Origin of First Cancer Cell To Metastasis

Melanoma Visualized in Live Zebrafish From Origin of First Cancer Cell To Metastasis

Researchers visualized the origins of cancer from the first affected cell through its spread in a live animal: the zebrafish. This research may change scientific understanding of melanoma and other cancers leading to new treatments that can be administered before the cancer has taken hold.

Interferon Has Little Benefit for Patients With Small Amounts of Melanoma in the Lymph Nodes

Interferon Has Little Benefit for Patients With Small Amounts of Melanoma in the Lymph Nodes

No evidence that interferon is necessary or helpful in cases of melanoma with minimal metastasis to the lymph nodes, according to the final results of the Sunbelt Melanoma Trial.

Treatment Goals Separate From Life Goals Among Patients With Advanced Cancer

Treatment Goals Separate From Life Goals Among Patients With Advanced Cancer

Patients with advanced cancer view life goals as distinct from and less important than treatment goals, according to a recent study.

Earlier and More Frequent Tanning Bed Use by Women Associated With Melanoma Incidence and Age at Diagnosis

Earlier and More Frequent Tanning Bed Use by Women Associated With Melanoma Incidence and Age at Diagnosis

Younger age at first use and more frequent use of indoor tanning beds are largely responsible for the steep increase in melanoma diagnoses in women younger than 40 years.

Inherited Genetic Markers Predictive of Survival Prognosis for Patients with Melanoma

Inherited Genetic Markers Predictive of Survival Prognosis for Patients with Melanoma

Prognosis for patients with cutaneous melanoma may be predicted by an inherited genetic marker providing a personalized tool to gauge a person's survival and determine if closer monitoring is needed in the years following surgery.

Prognosis Is Poor for Women With Pregnancy-Associated Melanoma

Prognosis Is Poor for Women With Pregnancy-Associated Melanoma

A recent study showed that women younger than 50 years who are pregnant or were recently pregnant at diagnosis of melanoma have a higher risk of death from the skin cancer.

Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma

Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma

Dabrafenib plus trametinib achieves good overall and progression-free survival in BRAF inhibitor-naïve patients with melanoma.

Using Mouse Avatars Aids Identification of Effective Targeted Therapies for Patients With Melanoma

Using Mouse Avatars Aids Identification of Effective Targeted Therapies for Patients With Melanoma

Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may halt disease progression in certain patients.

Circulating Tumor DNA More Effective Than LDH at Detecting Metastatic Melanoma Progression, Recurrence

Metastatic melanoma disease activity may be monitored via circulating tumor DNA, which has higher sensitivity than lactate dehydrogenase for detecting disease progression.

Familial Risk and Heritability of Cancer Is Higher Among Twins

Twins carry a significant excess familial risk for cancer overall and for specific types of cancer, including prostate, melanoma, breast, ovary, and uterus, according to a long-term follow-up study of twins in Nordic countries.

Noninvasive Scan May Offer Alternative to Biopsy in Skin Cancer

Noninvasive Scan May Offer Alternative to Biopsy in Skin Cancer

A noninvasive technique designed to identify melanin pigment naturally found in melanoma tumor cells shows promise for detecting the spread of skin cancer.

Novel Compound Improves Treatment Response and Reduces Recurrence of Melanoma

Novel Compound Improves Treatment Response and Reduces Recurrence of Melanoma

A new compound, SBI-756, targets a specific molecular machine known as the translation initiation complex. These structures are in every cell and play the critical role of translating mRNA into proteins.

International Study Charts Genetic Trajectory for Melanoma

International Study Charts Genetic Trajectory for Melanoma

An international team of scientists has mapped out the genetic trajectories taken by melanoma as it evolves from early skin lesions to malignant skin cancer.

Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy

Gut Bacteria Can Dramatically Amplify Cancer Immunotherapy

By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers were able to boost the ability of the animal's immune systems to attack tumor cells. The gains were comparable to treatment with checkpoint inhibitors.

New Developments in the Management of Advanced Melanoma - Role of Pembrolizumab

New Developments in the Management of Advanced Melanoma - Role of Pembrolizumab

[OncoTargets and Therapy] This research examines the use of pembrolizumab for the management of advanced melanoma.

Oxidative Stress Inhibits Melanoma Cell Metastasis

Oxidative Stress Inhibits Melanoma Cell Metastasis

Metastasizing cells undergo metabolic changes, increasing their ability to withstand oxidative stress.

Oncolytic Virus Therapy Approved for Treatment of Melanoma

Oncolytic Virus Therapy Approved for Treatment of Melanoma

Talimogene laherparapvec (Imlygic) is the first FDA-approved oncolytic virus therapy.

Resection of Abdominal Melanoma Metastases More Than Doubles Patient Survival Time

Patients with melanoma who undergo surgical resection of abdominal metastases live more than twice as long as those treated with drug therapy alone, according to novel research presented at the American College of Surgeons Clinical Congress 2015.

Lesion-directed Screening May be as Effective as Total-Body Examination

Lesion-directed Screening May be as Effective as Total-Body Examination

Lesion-directed screening is comparably effective and may be less time consuming.

Antioxidants May Be Harmful in Patients With Melanoma

Antioxidants May Be Harmful in Patients With Melanoma

Antioxidants may double the rate of metastasis in malignant melanoma.

Two-Drug Combination Significantly Improves Overall Survival in Patients With Melanoma

Current results from a clinical trial comparing a combination of two targeted therapies with a single-agent treatment for advanced melanoma has shown patients are living significantly longer with the combination therapy.

Training for Patients with Melanoma and Their Partners on Skin Examinations

Skin self-examination (SSE) training to aid early detection of melanoma recurrence is beneficial for patients with melanoma and their partners, and has additional benefits for those who report having low relationship quality because it gives them activities to do together.

Targeted Online Advertising May Effectively Deliver Skin Cancer Prevention Education

Targeted Online Advertising May Effectively Deliver Skin Cancer Prevention Education

Online targeted advertising based on Google search terms may be an effective way to deliver targeted skin cancer prevention education.

FDA Approves Immune-Oncology Combination for Melanoma

FDA Approves Immune-Oncology Combination for Melanoma

Accelerated approval for nivolumab and ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma.

Nivolumab in the treatment of malignant melanoma: Review of the literature

Nivolumab in the treatment of malignant melanoma: Review of the literature

[OncoTargets and Therapy] This review focuses on the functional and molecular characteristics of programmed death receptor-1 (PD-1) and the clinical efficacy and tolerability of its antibody, nivolumab.

Neutrophil/Lymphocyte Ratio is an Independent Prognostic in Melanoma

Neutrophil/Lymphocyte Ratio is an Independent Prognostic in Melanoma

Neutrophil/lymphocyte ratio (NLR) before initiating ipilimumab is an independent prognostic indicator of poor survival.

Trametinib: A MEK inhibitor for management of metastatic melanoma

Trametinib: A MEK inhibitor for management of metastatic melanoma

[OncoTargets and Therapy] This research examines the current data on the efficacy and safety of trametinib in patients with metastaticBRAF V600-positive melanoma.

Organ transplant recipients more likely to develop aggressive melanoma

Organ transplant recipients are twice as likely to develop melanoma as people who do not undergo a transplant, and are three times more likely to die of the dangerous skin cancer, new research suggests.

Foot site an independent risk factor for melanoma outcome

Foot site an independent risk factor for melanoma outcome

Foot melanoma seems to represent a specific subgroup and is a negative independent prognostic factor for disease-specific survival, according to a study.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs